Siemens Healthineers Receives FDA Approval for New Mammography Platform

Siemens Healthineers has gained FDA approval for its Mammomat B.brilliant, the company's first fully redesigned mammography platform in over a decade. The new 3D imaging feature, dubbed PlatinumTomo, enhances breast cancer screening by improving imaging accuracy through advanced technologies like flying focal spot and UltraHD reconstruction, reducing image blurring.

The Mammomat B.brilliant also captures 50-degree images, offering a clearer view of dense breast tissue, which is often difficult to assess using 2D scans. This system aims to increase diagnostic accuracy while reducing scan times by 35% compared to older models, making screening more efficient.

Unveiled in 2023 at the European Society of Breast Imaging congress, the system addresses patient comfort and speed. Siemens Healthineers' platform aims to improve both clinician and patient experiences, positioning itself as a significant innovation in breast cancer diagnostics.

Click here to read the original news story.